The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Risk of infections in CLL patients treated with time-limited targeted drug combinations
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, shares details about the risk of infection in patients with chronic lymphocytic leukemia (CLL) who are treated with time-limited drug combinations, highlighting the risk of neutropenia and infections. She emphasizes how clinicians must pay attention to the risk of infections in patients under these treatment regimens. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
